As you move your candidate toward approval, you’ll need to establish its PK/PD profile, determine immunogenicity, and identify relevant biomarkers that indicate efficacy and safety from discovery to the clinic. Inevitably, you’ll need to outsource one or more of these assessments, but have you considered the impact of your choice of vendors?
Join us to learn from a scientific advisor and experts in drug development as they explain key considerations for successful bioanalysis across the continuum. Discover common pitfalls and how to avoid them and understand difference between a provider and partner.
John Cook, BSc
Scientific Manager, Immunobiology
Keith Sutton, PhD
Scientific Advisor, Program Management
Colin Pattison, BSc
Associate Director, Bioanalysis
Have a scheduling conflict? Sign up even if you can't make it; we'll share the recording after.
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.